Now showing items 1-5 of 5
Evaluation of selected natural compounds as dual inhibitors of catechol-o-methyltransferase and monoamine oxidase
(Bentham Science, 2019)
Background: The most effective symptomatic treatment of Parkinson’s disease remains the metabolic precursor of dopamine, L-dopa. To enhance the efficacy of L-dopa, it is often combined with inhibitors of the enzymes, ...
An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4‐f]indole‐5,7‐dione and indole‐5,6‐dicarbonitrile derivatives
In recent studies, we have shown that pyrrolo[3,4‐f]indole‐5,7‐dione and indole‐5,6‐dicarbonitrile derivatives act as good potency in vitro inhibitors of the monoamine oxidase (MAO) enzymes. To expand on these series and ...
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase
In the present study, series of eight sesamol (1,3-benzodioxol-5-ol) and eight benzodioxane (2,3-dihydro-1,4-benzodioxine) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase ...
Nitrocatechol derivatives of chalcone as inhibitors of monoamine oxidase and Catechol-O-Methyltransferase
(Bentham Science, 2018)
Introduction: The efficacy of L-dopa in the treatment of Parkinson’s disease depends on its metabolic conversion to dopamine in the brain, however extensive peripheral metabolism of L-dopa diminishes its availability for ...
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework
Series of structurally diverse 2-imidazoline derivatives have been synthesized by condensation of substituted aldehydes with ethylenediamine, Pd-catalyzed N-arylation of 2-imidazolines and by the formation of 1,2,4-oxadiazoles ...